

Zsuzsanna Varga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550075/publications.pdf>

Version: 2024-02-01

89
papers

10,810
citations

147801

31
h-index

48315

88
g-index

94
all docs

94
docs citations

94
times ranked

22376
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic delay in moderately/poorly differentiated breast cancer types. <i>European Journal of Cancer Prevention</i> , 2022, 31, 152-157.	1.3	3
2	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2022, 118, 2385-2396.	3.8	14
3	Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. <i>Respiration</i> , 2022, 101, 155-165.	2.6	25
4	COVID-19 targets human adrenal glands. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 13-16.	11.4	46
5	Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2022, 12, 91.	3.3	13
6	Sexual dimorphism in COVID-19: potential clinical and public health implications. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 221-230.	11.4	78
7	Long-Term Persisting SARS-CoV-2 RNA and Pathological Findings: Lessons Learnt From a Series of 35 COVID-19 Autopsies. <i>Frontiers in Medicine</i> , 2022, 9, 778489.	2.6	18
8	Contemporary issues in breast pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1-3.	2.8	2
9	Abstract P3-09-14: Whole exome sequencing of matched primary and metastatic triple-negative breast cancer samples. <i>Cancer Research</i> , 2022, 82, P3-09-14-P3-09-14.	0.9	0
10	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	1.6	45
11	Code of practice for medical autopsies: a minimum standard position paper for pathology departments performing medical (hospital) autopsies in adults. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 509-517.	2.8	4
12	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. <i>Cancers</i> , 2022, 14, 2447.	3.7	6
13	Takotsubo Syndrome in Coronavirus Disease 2019. <i>American Journal of Cardiology</i> , 2021, 138, 118-120.	1.6	9
14	Higher prevalence of pulmonary macrothrombi in <sc>SARS-CoV</sc> than in influenza A: autopsy results from "Spanish flu" 1918/1919 in Switzerland to Coronavirus disease 2019. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 135-143.	3.0	29
15	Discrepancies between radiological and histological findings in preoperative core needle (CNB) and vacuum-assisted (VAB) breast biopsies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 749-754.	2.5	8
16	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	2.9	13
17	SARS-CoV-2 leads to a small vessel endotheliitis in the heart. <i>EBioMedicine</i> , 2021, 63, 103182.	6.1	93
18	Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. <i>PLoS ONE</i> , 2021, 16, e0255580.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 4.	5.0	23
20	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue – A pilot study. <i>Experimental and Molecular Pathology</i> , 2021, 123, 104705.	2.1	1
21	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	2.9	19
22	Large and Small Cerebral Vessel Involvement in Severe COVID-19. <i>Stroke</i> , 2020, 51, 3719-3722.	2.0	89
23	Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 759-770.	2.5	16
24	A Requirement for p120-catenin in the metastasis of invasive ductal breast cancer. <i>Journal of Cell Science</i> , 2020, 134, .	2.0	3
25	Case report of sequential bilateral spontaneous pneumothorax in a never-ventilated, lung-healthy COVID-19-patient. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 441-445.	0.6	10
26	Methylation Profile of X-Chromosome-Related Genes in Male Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 784.	2.8	8
27	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, 20.	5.2	25
28	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. <i>Lancet, The</i> , 2020, 395, e100.	13.7	64
29	Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 311-319.	2.5	9
30	Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations. <i>Human Pathology</i> , 2020, 98, 64-73.	2.0	5
31	The single-cell pathology landscape of breast cancer. <i>Nature</i> , 2020, 578, 615-620.	27.8	582
32	Inter-observer reproducibility of classical lobular neoplasia (B3 lesions) in preoperative breast biopsies: a study of the Swiss Working Group of breast and gynecopathologists. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1473-1478.	2.5	6
33	Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet, The</i> , 2020, 395, 1417-1418.	13.7	5,100
34	Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 2125-2131.	1.1	4
35	Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2983-2994.	2.5	11
36	Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. <i>Scientific Reports</i> , 2019, 9, 13534.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	5.2	21
38	Author's reply to: Comparing the performance of gene expression assays in breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1163-1164.	5.1	0
39	Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial. <i>Annals of Surgical Oncology</i> , 2019, 26, 1254-1262.	1.5	43
40	Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens. <i>Breast Cancer</i> , 2019, 26, 452-458.	2.9	17
41	Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 882-893.	5.1	32
42	Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). <i>Breast Cancer Research and Treatment</i> , 2019, 174, 279-296.	2.5	179
43	Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , 2018, 39, 19-23.	2.2	39
44	Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 865-874.	2.5	5
45	Overexpression of Lox in triple-negative breast cancer. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 98-102.	1.3	15
46	Influence of breast cancer opportunistic screening on aesthetic surgical outcome: A single-center retrospective study in Switzerland. <i>Breast Journal</i> , 2018, 24, 285-290.	1.0	5
47	Preferential expression of NY-BR-1 and GATA-3 in male breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 199-204.	2.5	5
48	Author's response. <i>Breast Journal</i> , 2018, 24, 1139-1139.	1.0	0
49	X chromosome gain is related to increased androgen receptor expression in male breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 155-163.	2.8	10
50	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	12.8	105
51	Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 118.	4.4	15
52	The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ER±. <i>Nature</i> , 2017, 541, 541-545.	27.8	114
53	Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. <i>Cancer Research</i> , 2017, 77, 2148-2160.	0.9	36
54	Invasive lobular carcinoma with extracellular mucin production—a novel pattern of lobular carcinomas of the breast. Clinico-pathological description of eight cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 3-12.	2.8	31

#	ARTICLE	IF	CITATIONS
55	MRI-guided breast vacuum biopsy: Localization of the lesion without contrast-agent application using diffusion-weighted imaging. <i>Magnetic Resonance Imaging</i> , 2017, 38, 1-5.	1.8	8
56	histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. <i>Nature Methods</i> , 2017, 14, 873-876.	19.0	470
57	Long-term prognosis of young breast cancer patients (â%40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017, 7, e017842.	1.9	11
58	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyperÂ®. <i>Breast Cancer Research</i> , 2017, 19, 55.	5.0	29
59	A Micro CT Study in Patients with Breast Microcalcifications Using a Mathematical Algorithm to Assess 3D Structure. <i>PLoS ONE</i> , 2017, 12, e0169349.	2.5	5
60	Long-term outcome of breast cancer patients diagnosed â%40 years according to breast cancer subtype in the absence of adjuvant systemic therapy: The PARADIGM initiative.. <i>Journal of Clinical Oncology</i> , 2017, 35, 535-535.	1.6	0
61	Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3259-3264.	1.1	4
62	HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy. <i>PLoS ONE</i> , 2016, 11, e0159176.	2.5	22
63	Assessment of the extent of microcalcifications to predict the size of a ductal carcinoma in situ: comparison between tomosynthesis and conventional mammography. <i>Clinical Imaging</i> , 2016, 40, 1269-1273.	1.5	11
64	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. <i>Oncolmmunology</i> , 2016, 5, e1153208.	4.6	36
65	G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1115177.	4.6	123
66	Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2Î± in invasive breast cancer cells. <i>Oncotarget</i> , 2016, 7, 31153-31165.	1.8	18
67	MAGI3â€™AKT3 fusion in breast cancer amended. <i>Nature</i> , 2015, 520, E11-E12.	27.8	22
68	Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study. <i>PLoS ONE</i> , 2015, 10, e0123435.	2.5	32
69	Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience. <i>PLoS ONE</i> , 2015, 10, e0140652.	2.5	55
70	The G Protein-Coupled Estrogen Receptor (GPER) Is Expressed in Two Different Subcellular Localizations Reflecting Distinct Tumor Properties in Breast Cancer. <i>PLoS ONE</i> , 2014, 9, e83296.	2.5	49
71	Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification. <i>PLoS ONE</i> , 2014, 9, e105961.	2.5	22
72	Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. <i>Nature Methods</i> , 2014, 11, 417-422.	19.0	1,430

#	ARTICLE	IF	CITATIONS
73	Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. <i>Nature</i> , 2014, 515, 130-133.	27.8	556
74	Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. <i>Breast</i> , 2014, 23, 259-263.	2.2	53
75	Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. <i>BMC Cancer</i> , 2013, 13, 615.	2.6	84
76	Stability and prognostic value of Slug, Sox9 and Sox10 expression in breast cancers treated with neoadjuvant chemotherapy. <i>SpringerPlus</i> , 2013, 2, 695.	1.2	22
77	Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer. <i>PLoS ONE</i> , 2013, 8, e58483.	2.5	59
78	Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 925-935.	2.5	39
79	Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 929-935.	2.5	11
80	Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. <i>Pathology International</i> , 2012, 62, 254-263.	1.3	12
81	How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists. <i>PLoS ONE</i> , 2012, 7, e37379.	2.5	175
82	Iatrogenic nephrocalcinosis with acute renal failure: an underestimated complication after parathyroidectomy?. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 551-554.	2.9	2
83	Infiltrating Lobular Carcinoma: Four Case Illustrations. <i>Breast Disease</i> , 2009, 30, 57-61.	0.8	0
84	Histology and Immunophenotype of Invasive Lobular Breast Cancer. <i>Daily Practice and Pitfalls. Breast Disease</i> , 2009, 30, 15-19.	0.8	10
85	NY-ESO-1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. <i>International Journal of Cancer</i> , 2007, 120, 2411-2417.	5.1	65
86	Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 2745-2751.	7.0	42
87	Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 136-141.	2.8	46
88	Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments. <i>Breast Cancer Research and Treatment</i> , 1999, 57, 215-219.	2.5	6
89	Metaplastic lipid-rich carcinoma of the breast. <i>Pathology International</i> , 1998, 48, 912-916.	1.3	16